爱普列特联合哈乐治疗良性前列腺增生临床疗效观察

目的观察良性前列腺增生症(BPH)患者使用爱普列特联合哈乐治疗前后症状及尿动力学改变,探讨其治疗BPH的临床意义。方法门诊随诊初诊BPH患者38例,在接受爱普列特联合哈乐治疗前及治疗12周后查尿动力学改变、残余尿及症状比较。结果国际前列腺症状评分表(IPSS)由治疗前的(21.4±5.1)分显著改善为(13.2±3.9)分(P<0.05),最大尿流率由治疗前的(7.6±1.3)mL/s增加到治疗后的(18.3±2.2)mL/s(P<0.05),残余尿量由治疗前的(75±7.1)mL减少到治疗后的(36±5.2)mL(P<0.05),症状明显改善32例,治疗有效率占84%。结论爱普列特联合哈乐能有效提高尿流率,减少IPSS评分,减少残余尿量,同时不良反应小,是临床治疗BPH的理想选择。

The clinical efficacy of Epristeride and Harold in the treatment of benign prostatic hyperplasia

Objective To observe symptoms and urodynamic changes of patients with benign prostatic hyperplasia（BPH） before and after the combined treatment of Epristeride and Harold,and to investigate clinical significance of the combined treatment.Methods 38 outpatients with BPH underwent Epristeride and Harold received treatment in the 12 weeks,and the changes of urodynamic,residual urine and the symptoms were analyzed before and after the treatment.Results IPSS decreased from 21.4±5.1 to 13.2±3.9（P0.05）,and the maximum urinary flow rate increased from（7.6±1.3）mL/s to（18.3±2.2）mL/s（P0.05）after treatment,the residual urine decreased from（75±7.1）mL to（36±5.2）mL（P0.05）after treatment,symptoms improved significantly in 32 cases,with an effective rate of 84%.Conclusion The combined treatment of Epristeride and Harold can improve urinary flow rate and reduce the IPSS score,and reduce the residual urine volume,with fewer side-effects and it is ideal clinical treatment of BPH.